Biolase (BIOL)
(Delayed Data from OTC)
$0.07 USD
-0.01 (-14.62%)
Updated Jul 25, 2024 03:52 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Biolase, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7 | 4 | 30 | 18 | 6 |
Receivables | 5 | 6 | 4 | 3 | 9 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 11 | 16 | 13 | 11 | 11 |
Other Current Assets | 1 | 3 | 2 | 3 | 1 |
Total Current Assets | 25 | 29 | 49 | 35 | 27 |
Net Property & Equipment | 6 | 4 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 3 | 3 | 3 | 3 | 3 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 35 | 38 | 55 | 41 | 32 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 6 | 3 | 3 | 5 |
Current Portion Long-Term Debt | 2 | 1 | 0 | 0 | 13 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 9 | 8 | 7 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 2 | 2 |
Total Current Liabilities | 20 | 18 | 14 | 11 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 12 | 13 | 14 | 16 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 33 | 33 | 30 | 31 | 28 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 2 | 0 | 0 | 0 | 4 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 317 | 302 | 293 | 262 | 236 |
Retained Earnings | -317 | -296 | -268 | -251 | -235 |
Other Equity | -1 | -1 | -1 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2 | 5 | 25 | 10 | 4 |
Total Liabilities & Shareholder's Equity | 35 | 38 | 55 | 41 | 32 |
Total Common Equity | 0 | 5 | 25 | 10 | 0 |
Shares Outstanding | 3.40 | 0.00 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | -0.07 | 4.89 | 25.18 | 9.91 | 0.37 |
Fiscal Year End for Biolase, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 6 | 7 | 8 | 7 |
Receivables | NA | 6 | 5 | 4 | 6 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 11 | 11 | 14 | 13 |
Other Current Assets | NA | 2 | 1 | 2 | 2 |
Total Current Assets | NA | 25 | 25 | 28 | 28 |
Net Property & Equipment | NA | 5 | 6 | 6 | 6 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 3 | 3 | 3 | 3 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 34 | 35 | 39 | 40 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 6 | 7 | 6 |
Current Portion Long-Term Debt | NA | 3 | 2 | 3 | 2 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 8 | 9 | 8 | 8 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 6 | 2 | 2 | 2 |
Total Current Liabilities | NA | 21 | 20 | 20 | 18 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 11 | 12 | 11 | 12 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 34 | 33 | 33 | 32 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 2 | 2 | 6 | 1 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 322 | 317 | 313 | 314 |
Retained Earnings | NA | -323 | -317 | -311 | -307 |
Other Equity | NA | -1 | -1 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 0 | 2 | 6 | 7 |
Total Liabilities & Shareholder's Equity | NA | 34 | 35 | 39 | 40 |
Total Common Equity | 0 | -2 | 0 | 0 | 7 |
Shares Outstanding | 33.40 | 33.20 | 3.40 | 2.20 | 1.00 |
Book Value Per Share | 0.00 | -0.06 | -0.07 | 0.15 | 6.62 |